2 June 2016 EMA/COMP/278477/2016 Procedure Management and Committees Support Division Committee for Orphan Medicinal Products (COMP) Minutes for the meeting on 19-21 April 2016 Chair: Bruno Sepodes – Vice-Chair: Lesley Greene 19 April 2016, 09:00-18:30, room 2F 20 April 2016, 09:00-18:30, room 2F 21 April 2016, 08:30-12:30, room 2F Disclaimers Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised. Of note, this set of minutes is a working document primarily designed for COMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Introduction 5 1.1. Welcome and declarations of interest of members and experts .............................. 5 1.2. Adoption of agenda................................................................................................. 5 1.3. Adoption of the minutes ......................................................................................... 5 2. Applications for orphan medicinal product designation 5 2.1. For opinion ............................................................................................................. 5 2.1.1. Arimoclomol citrate - EMA/OD/256/15 .......................................................................... 5 2.1.2. - EMA/OD/220/15 ...................................................................................................... 6 2.1.3. - EMA/OD/146/15 ...................................................................................................... 7 2.1.4. Fc- and CDR-modified humanized monoclonal antibody against C5 - EMA/OD/246/15 ........ 8 2.1.5. - EMA/OD/258/15 ...................................................................................................... 9 2.2. For discussion / preparation for an opinion ............................................................ 9 2.2.1. (R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6- dihydrobenzo[h]quinazolin-2-amine dihydrochloride - EMA/OD/245/15 ............................ 9 2.2.2. - EMA/OD/023/16 .................................................................................................... 10 2.2.3. - EMA/OD/016/16 .................................................................................................... 10 2.2.4. 4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1- piperazinecarboxamide - EMA/OD/208/15 ................................................................... 10 2.2.5. - EMA/OD/019/16 .................................................................................................... 11 2.2.6. - EMA/OD/020/16 .................................................................................................... 11 2.2.7. - EMA/OD/021/16 .................................................................................................... 11 2.2.8. - EMA/OD/018/16 .................................................................................................... 11 2.2.9. Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene - EMA/OD/024/16 ............................................................................................ 11 2.2.10. - EMA/OD/022/16 .................................................................................................... 12 2.2.11. - EMA/OD/008/16 .................................................................................................... 12 2.2.12. - EMA/OD/009/16 .................................................................................................... 12 2.2.13. - EMA/OD/010/16 .................................................................................................... 12 2.2.14. H-Phe-Ser-Arg-Tyr-Ala-Arg-OH-Acetate - EMA/OD/011/16............................................ 13 2.2.15. - EMA/OD/014/16 .................................................................................................... 13 2.2.16. - EMA/OD/004/16 .................................................................................................... 13 2.2.17. - EMA/OD/007/16 .................................................................................................... 13 2.2.18. - EMA/OD/001/16 .................................................................................................... 14 2.2.19. - EMA/OD/005/16 .................................................................................................... 14 2.2.20. Pentosan polysulfate sodium - EMA/OD/003/16 ........................................................... 14 2.2.21. Polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase - EMA/OD/025/16 ...................................................................................................... 14 Committee for Orphan Medicinal Products (COMP) EMA/COMP/278477/2016 Page 2/29 2.2.22. Recombinant adeno-associated viral vector containing the human RPGR gene - EMA/OD/002/16 ...................................................................................................... 15 2.2.23. Rimiducid - EMA/OD/017/16 ..................................................................................... 15 2.2.24. Rovalpituzumab tesirine - EMA/OD/015/16 ................................................................. 16 2.2.25. Sodium nitrite and ethylenediaminetetraacetic acid - EMA/OD/013/16............................ 17 2.2.26. Temsirolimus - EMA/OD/027/16 ................................................................................ 17 2.2.27. Vemurafenib - EMA/OD/026/16 ................................................................................. 18 2.3. Amendment of the COMP opinions ........................................................................ 19 2.3.1. (S)-ethyl 2-amino-3-(4-(2-amino-6((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)- 2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate – EMA/OD/047/09, EU/3/09/66 .. 19 2.4. COMP opinions adopted via written procedure following previous meeting .......... 19 2.5. Appeal .................................................................................................................. 19 2.6. Nominations ......................................................................................................... 19 2.6.1. New applications for orphan medicinal product designation - Appointment of COMP coordinators ............................................................................................................ 19 2.7. Evaluation on-going .............................................................................................. 19 3. Requests for protocol assistance with significant benefit question 20 3.1. Ongoing procedures ............................................................................................. 20 3.1.1. - ............................................................................................................................ 20 3.1.2. - ............................................................................................................................ 20 3.2. Finalised letters .................................................................................................... 20 3.2.1. - ............................................................................................................................ 20 3.2.2. - ............................................................................................................................ 20 3.2.3. - ............................................................................................................................ 20 3.3. New requests ........................................................................................................ 20 4. Review of orphan designation for orphan medicinal products for marketing authorisation 21 4.1. Orphan designated products for which CHMP opinions have been adopted .......... 21 4.1.1. Darzalex – daratumumab - EMA/OD/038/13, EU/3/13/1153 , EMEA/H/C/004077 ............ 21 4.1.2. Empliciti - elotuzumab - EMA/OD/061/12, EU/3/12/1037, EMEA/H/C/003967 ................. 23 4.1.3. Galafold - migalastat – EMEA/OD/105/05, EU/3/06/368, EMEA/H/C/004059 .................. 23 4.1.4. Strimvelis - autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence EMEA/OD/053/05, EU/3/05/313, EMEA/H/C/003854 ..............................................................................